Stem definition | Drug id | CAS RN |
---|---|---|
systemic antifungal agents, miconazole derivatives | 983 | 27220-47-9 |
Dose | Unit | Route |
---|---|---|
0.10 | g | V |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 23, 1982 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute motor-sensory axonal neuropathy | 100.76 | 25.10 | 16 | 1897 | 272 | 50602939 |
Rash maculo-papular | 83.43 | 25.10 | 33 | 1880 | 26608 | 50576603 |
Acute generalised exanthematous pustulosis | 70.34 | 25.10 | 22 | 1891 | 8916 | 50594295 |
Hypothalamic pituitary adrenal axis suppression | 49.88 | 25.10 | 8 | 1905 | 145 | 50603066 |
International normalised ratio increased | 47.78 | 25.10 | 26 | 1887 | 43126 | 50560085 |
Purpura senile | 46.03 | 25.10 | 9 | 1904 | 520 | 50602691 |
Tarsal tunnel syndrome | 45.86 | 25.10 | 9 | 1904 | 530 | 50602681 |
Granulomatous liver disease | 42.98 | 25.10 | 9 | 1904 | 734 | 50602477 |
Oedema mouth | 42.41 | 25.10 | 11 | 1902 | 2279 | 50600932 |
Drug interaction | 41.48 | 25.10 | 44 | 1869 | 199577 | 50403634 |
Eosinophilia | 41.10 | 25.10 | 18 | 1895 | 18634 | 50584577 |
Resorption bone increased | 40.21 | 25.10 | 9 | 1904 | 1002 | 50602209 |
Lip oedema | 38.79 | 25.10 | 11 | 1902 | 3182 | 50600029 |
Vestibular disorder | 38.18 | 25.10 | 9 | 1904 | 1260 | 50601951 |
Dermatitis exfoliative generalised | 34.53 | 25.10 | 10 | 1903 | 3116 | 50600095 |
Folate deficiency | 34.32 | 25.10 | 9 | 1904 | 1946 | 50601265 |
Drug reaction with eosinophilia and systemic symptoms | 33.88 | 25.10 | 18 | 1895 | 28406 | 50574805 |
Rash scarlatiniform | 30.21 | 25.10 | 5 | 1908 | 111 | 50603100 |
Vertigo positional | 27.58 | 25.10 | 8 | 1905 | 2503 | 50600708 |
Osmotic demyelination syndrome | 27.50 | 25.10 | 6 | 1907 | 594 | 50602617 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Procedural haemorrhage | 50.57 | 29.95 | 12 | 844 | 2271 | 29571400 |
Pulmonary haemorrhage | 33.96 | 29.95 | 12 | 844 | 9258 | 29564413 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rash maculo-papular | 102.38 | 23.74 | 45 | 2404 | 46981 | 64449302 |
Acute motor-sensory axonal neuropathy | 94.95 | 23.74 | 16 | 2433 | 396 | 64495887 |
Acute generalised exanthematous pustulosis | 83.57 | 23.74 | 28 | 2421 | 14030 | 64482253 |
International normalised ratio increased | 54.13 | 23.74 | 35 | 2414 | 79132 | 64417151 |
Tarsal tunnel syndrome | 46.40 | 23.74 | 9 | 2440 | 496 | 64495787 |
Purpura senile | 46.29 | 23.74 | 9 | 2440 | 502 | 64495781 |
Hypothalamic pituitary adrenal axis suppression | 44.62 | 23.74 | 8 | 2441 | 286 | 64495997 |
Drug reaction with eosinophilia and systemic symptoms | 42.11 | 23.74 | 26 | 2423 | 54191 | 64442092 |
Toxic skin eruption | 40.43 | 23.74 | 18 | 2431 | 19266 | 64477017 |
Procedural haemorrhage | 39.89 | 23.74 | 12 | 2437 | 4240 | 64492043 |
Resorption bone increased | 38.88 | 23.74 | 9 | 2440 | 1159 | 64495124 |
Eosinophilia | 36.72 | 23.74 | 21 | 2428 | 38055 | 64458228 |
Oedema mouth | 35.31 | 23.74 | 10 | 2439 | 2863 | 64493420 |
Drug interaction | 33.96 | 23.74 | 54 | 2395 | 362029 | 64134254 |
Granulomatous liver disease | 33.26 | 23.74 | 8 | 2441 | 1214 | 64495069 |
Vestibular disorder | 32.85 | 23.74 | 9 | 2440 | 2284 | 64493999 |
Folate deficiency | 31.19 | 23.74 | 9 | 2440 | 2754 | 64493529 |
Lip oedema | 29.49 | 23.74 | 10 | 2439 | 5179 | 64491104 |
Dermatitis exfoliative generalised | 28.20 | 23.74 | 10 | 2439 | 5906 | 64490377 |
Pulmonary haemorrhage | 26.72 | 23.74 | 12 | 2437 | 13097 | 64483186 |
Rash scarlatiniform | 26.64 | 23.74 | 5 | 2444 | 231 | 64496052 |
Rash pruritic | 26.58 | 23.74 | 20 | 2429 | 57384 | 64438899 |
Vertigo positional | 26.38 | 23.74 | 8 | 2441 | 2903 | 64493380 |
None
Source | Code | Description |
---|---|---|
ATC | D01AC03 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
ATC | G01AF05 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
ATC | G01AF55 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
FDA CS | M0002083 | Azoles |
FDA EPC | N0000175487 | Azole Antifungal |
MeSH PA | D058888 | 14-alpha Demethylase Inhibitors |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000935 | Antifungal Agents |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D065088 | Steroid Synthesis Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tinea pedis | indication | 6020002 | DOID:12403 |
Candidiasis of skin | indication | 49883006 | |
Pityriasis versicolor | indication | 56454009 | DOID:9060 |
Tinea corporis | indication | 84849002 | |
Tinea cruris | indication | 399029005 | |
Paronychia | off-label use | 71906005 | DOID:13117 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.49 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Cannabinoid receptor 1 | GPCR | Ki | 4.54 | DRUG MATRIX | |||||
Mu-type opioid receptor | GPCR | Ki | 5.64 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.34 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 5.37 | DRUG MATRIX | |||||
Adenosine receptor A2a | GPCR | Ki | 5.09 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 5.05 | DRUG MATRIX | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 7.30 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.65 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.62 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.03 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.94 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.36 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.20 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.30 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.57 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.81 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.20 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.94 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.42 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.53 | DRUG MATRIX | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 5.34 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 6.18 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6.40 | DRUG MATRIX | |||||
Adenosine receptor A1 | GPCR | Ki | 5.01 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.74 | DRUG MATRIX | |||||
D(4) dopamine receptor | GPCR | Ki | 5.49 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 5.36 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.46 | DRUG MATRIX | |||||
Delta-type opioid receptor | GPCR | Ki | 6.29 | DRUG MATRIX | |||||
Acetylcholinesterase | Enzyme | IC50 | 4.86 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.70 | DRUG MATRIX | |||||
Cytochrome P450 1A2 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
Epidermal growth factor receptor | Kinase | IC50 | 4.49 | DRUG MATRIX | |||||
Substance-P receptor | GPCR | Ki | 5.19 | DRUG MATRIX | |||||
Steroid 17-alpha-hydroxylase/17,20 lyase | Enzyme | Ki | 6.49 | CHEMBL | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 7.40 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 4.92 | DRUG MATRIX | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 4.86 | DRUG MATRIX | |||||
Thromboxane-A synthase | Enzyme | IC50 | 7.54 | DRUG MATRIX | |||||
Lanosterol 14-alpha demethylase | Enzyme | IC50 | 7.30 | CHEMBL | |||||
Matrix metalloproteinase-9 | Enzyme | IC50 | 5.16 | DRUG MATRIX | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 5.09 | CHEMBL | |||||
Substance-K receptor | GPCR | Ki | 5.70 | DRUG MATRIX | |||||
Melanocortin receptor 5 | GPCR | Ki | 4.43 | DRUG MATRIX | |||||
Melanocortin receptor 3 | GPCR | Ki | 4.50 | DRUG MATRIX | |||||
Neuropeptide Y receptor type 2 | GPCR | Ki | 4.96 | DRUG MATRIX | |||||
Malate dehydrogenase cytoplasmic | Enzyme | IC50 | 4.60 | CHEMBL | |||||
Calcium release-activated calcium channel protein 1 | Ion channel | IC50 | 4.77 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Ki | 5.13 | DRUG MATRIX | |||||
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase | Enzyme | IC50 | 6.51 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 4.60 | CHEMBL | |||||
Androgen receptor | Transcription factor | Ki | 5.17 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.00 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 5.50 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 5.88 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 4.67 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 4.79 | CHEMBL | |||||
Acetylcholinesterase | Enzyme | IC50 | 4.65 | CHEMBL | |||||
Cholinesterase | Enzyme | IC50 | 4.76 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | Kd | 6.70 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.12 | CHEMBL | |||||
Mycocyclosin synthase | Enzyme | Kd | 7.14 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.95 | CHEMBL |
ID | Source |
---|---|
4019740 | VUID |
N0000147832 | NUI |
D00881 | KEGG_DRUG |
24169-02-6 | SECONDARY_CAS_RN |
4018560 | VANDF |
4019740 | VANDF |
C0013547 | UMLSCUI |
CHEBI:4754 | CHEBI |
ECN | PDB_CHEM_ID |
CHEMBL808 | ChEMBL_ID |
DB01127 | DRUGBANK_ID |
CHEMBL1201049 | ChEMBL_ID |
D004464 | MESH_DESCRIPTOR_UI |
3198 | PUBCHEM_CID |
2446 | IUPHAR_LIGAND_ID |
3189 | INN_ID |
6Z1Y2V4A7M | UNII |
142434 | RXNORM |
45569 | MMSL |
4650 | MMSL |
002923 | NDDF |
002924 | NDDF |
18952006 | SNOMEDCT_US |
373471002 | SNOMEDCT_US |
73827006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-892 | CREAM | 10 mg | TOPICAL | ANDA | 17 sections |
ECOZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23710-100 | AEROSOL, FOAM | 10 mg | TOPICAL | NDA | 30 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-956 | CREAM | 10 mg | TOPICAL | ANDA | 17 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-466 | CREAM | 10 mg | TOPICAL | ANDA | 17 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1303 | CREAM | 10 mg | TOPICAL | ANDA | 20 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52565-022 | CREAM | 10 mg | TOPICAL | ANDA | 18 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5042 | CREAM | 10 mg | TOPICAL | ANDA | 17 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8645 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8645 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8646 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8646 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8647 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8647 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63739-085 | CREAM | 10 mg | TOPICAL | ANDA | 13 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68788-7406 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68788-7406 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68788-8170 | CREAM | 10 mg | TOPICAL | ANDA | 17 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68788-8174 | CREAM | 10 mg | TOPICAL | ANDA | 20 sections |
Econazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70512-029 | CREAM | 10 mg | TOPICAL | ANDA | 12 sections |
PM EXTERNAL | HUMAN OTC DRUG LABEL | 4 | 72689-0038 | SOLUTION | 10 mg | TOPICAL | unapproved drug other | 7 sections |
ECONAZOLE NITRATE 1% / NIACINAMIDE 4% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-2073 | CREAM | 1 g | TOPICAL | unapproved drug other | 4 sections |
071023 ECONAZOLE NITRATE 1% / NIACINAMIDE 4% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-2218 | CREAM | 1 g | TOPICAL | unapproved drug other | 4 sections |